Screener / SEC EDGAR /CIK 0001699031 /10-K filed Mar 12, 2026, compared with Mar 5, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

GRAIL, Inc. GRAL

Compare with peers Embed
The 10-K against last year's

305 changes: 71 added, 50 removed, 181 reworded, 3 quiet changes

10-K Mar 12, 2026 vs Mar 5, 2025

10-K 0001628280-26-017319 (Mar 12, 2026) vs 10-K 0001699031-25-000041 (Mar 5, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

526 paragraphs · 44 new · 145 reworded · 23 gone · 10-K Mar 12, 2026 against Mar 5, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 132 · 49% changed Every version of it
of our PMA submission for Galleri, which would negatively impact could materially affect our business, financial condition, results of operations, and growth prospects. prospects and cause the price of our common stock to decline.
Paragraph 324 · 48% changed Every version of it
In particular, For example, we recently announced the topline results of our NHS-Galleri Trial in the United Kingdom, we are working with United. In May 2024, the NHS determined, based on data from an early analysis of Galleri test performance results in the intervention arm from the prevalent screening round of the NHS-Galleri Trial, not to initiate an implementation pilot in England prior to the final trial results. We submitted to NHS England and to complete our NHS-Galleri Trial. It the FDA information from the prevalent screening round. Various factors are likely to cause the final results to differ from the prevalent screening round results. Further, it is possible that the early preliminary, interim or final data may not be as we expect, may be inconsistent with prior NHS-Galleri Trial data, or with other studies we have conducted, or may be unsuitable to the NHS, any NHS or the FDA. Importantly, preliminary or interim data may be focused on different endpoints than the overall study. The prevalent screening round results that we announced and provided to the NHS and FDA were predominantly focused on performance characteristics of which the Galleri test, whereas the primary endpoint and a number of secondary endpoints of the trial were focused on clinical utility measures like cancer stage shift that can only be measured through annual testing over a number of years. Similarly, in October 2025, performance and safety results from the first approximately 25,000 participants of the PATHFINDER 2 study were presented at the ESMO Congress 2025. PATHFINDER 2 was initiated in 2021 to evaluate the safety and performance of the Galleri test when added to standard of care single cancer screening in 35,878 adults aged 50 years and older with no clinical suspicion of cancer. Results from the full approximately 35,000 participants in the PATHFINDER 2 study were generally consistent with the results presented at ESMO. While we did not include full performance and safety data from the additional 10,000 patients in our initial PMA submission, it is possible that the FDA could require these data to confirm study performance. Any unexpected, unsuitable, or inconsistent results could have a significant adverse impact on the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our ability to achieve CMS or private payor reimbursement or coverage, our brand and reputation, our business, and our growth prospects.
Paragraph 387 · 48% changed Every version of it
Changes in funding, global health concerns leadership, resources or disruptions prioritization, or other disruptions, in the U.S. or international government, including at the FDA, other government agencies, and notified bodies bodies, could hinder their our ability to hire and retain key leadership and other personnel, develop, approve, certify, commercialize or receive reimbursement for our test.
Paragraph 23 · 47% changed Every version of it
Our products require a number of complex and sophisticated biochemical and bioinformatics processes, which could be adversely impacted by a number of different factors. An operational or technological failure in one of these complex processes or fluctuations in external variables may result in performance characteristics, such as sensitivity or specificity rates, that are lower than we anticipate or that vary between test runs or in a higher than anticipated number of tests that fail to produce results. In addition, we continue to evaluate and refine our algorithms and other processes under development. These refinements may inadvertently result in unanticipated issues that may reduce our performance characteristics, such as sensitivity or specificity rates, or otherwise adversely affect the performance of our tests and their results. Galleri was launched in the United States as an LDT in mid-2021 and an updated version was launched in December 2024. The FDA has granted breakthrough device designation for Galleri. We plan to complete a PMA submission for a further updated version of our Galleri test. We may also be required or decide voluntarily to seek clearance or approval from the FDA for future products. However, the FDA recently finalized a regulation pursuant to which it plans to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, if it imposes new, different or earlier significant obligations, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business will be substantially harmed.
Paragraph 259 · 46% changed Every version of it
We have launched Galleri as a laboratory developed test (“LDT”) an LDT in the United States. The In 2024, the FDA recently finalized a regulation that has been successfully challenged in federal court, pursuant to which it plans the FDA planned to subject LDTs to medical device requirements through a phase-out of its historical policy of enforcement discretion over LDTs over a period of four years. The phase-in of medical device requirements to LDTs, including the potential requirement for FDA marketing authorization, if it imposes new, different or earlier significant obligations, will be costly and time-consuming, and if we fail to comply with such requirements, or if we cannot ultimately obtain marketing authorization for our LDTs where required, our business will be substantially harmed. A federal court recently vacated this rule.
Paragraph 390 · 46% changed Every version of it
The ability of In addition, in recent years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, foreign regulatory agencies, have had to furlough critical FDA employees and notified bodies to review stop critical activities, including during an extended shutdown between October 1, 2025 and clear, approve, or certify new products or changes to existing products can be affected by November 12, 2025. Similar shutdowns could have a variety broad range of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s, foreign regulatory agencies’, and notified bodies’ ability to hire and retain key personnel and accept the payment of user fees, government shutdowns, and other events that may otherwise affect the FDA’s foreign regulatory agencies’ and notified bodies’ ability to perform routine functions. For example, in January 2025, federal employees were offered the option to make a deferred resignation, which, if a significant number of employees elect, could impact the workforce and resources of the FDA available to review products such as ours. Average review times at the FDA, foreign regulatory agencies, and notified bodies have fluctuated in recent years as a result of these factors. negative effects on our business. Disruptions at the FDA, other agencies, and notified bodies caused by these or other shutdowns, may also slow the time necessary for new medical devices or modifications to cleared, be cleared and approved, or certified medical devices to be reviewed and/or approved, or certified by necessary government agencies or notified bodies, or delay payment for currently reimbursed research, such as our REACH study, or reimbursed products in the future, which would adversely affect our business. For example, in recent years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. Recently, In addition, during the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. If a prolonged government shutdown occurs, or if new global health concerns prevent the FDA, other regulatory authorities, or notified bodies from conducting their regular activities, it could significantly impact the ability of the FDA, other regulatory authorities, or notified bodies to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Paragraph 111 · 43% changed Every version of it
current version to conduct a non-inferiority study. With respect to Galleri, we intend to conduct one or more bridging studies to measure and evaluate concordance, performance and safety of the subsequent, updated version of Galleri (for which we are submitting our PMA) using previously collected clinical study data and other samples. Any such bridging study will need to be agreed upon with regulatory authorities and may be unsuccessful or insufficient to support approval. If unsuccessful or insufficient, we would be required to revert to the existing a prior version of the test and forego, forgo, or be delayed in, implementing any perceived or potential updates, including enhancements. Reverting enhancements, or further enhance, modify or update to the existing a new version of the test and run additional bridging studies. Reverting to a prior version of the test or running additional bridging studies may cause delays in our efforts to obtain PMA submission timeline. approval for Galleri or any new product. Additionally, planned improvements to our products may cause unintentional technical, logistical or other issues. For example, in In late 2024, we began use of a new an updated commercial version of Galleri in commercial channels which channels. This version incorporates an industrial scale platform with significant automation and is intended to enable us to scale more efficiently with future demand. In connection with implementation of this new version of Galleri, we have initially experienced and may continue to experience increased turnaround times times, re-processing costs and order cancellations. If we are unable to adequately prevent these issues from occurring, or to adequately identify and remedy these issues, we may experience reputational harm, lose customers, need to offer discounts, or suffer other negative consequences. Our failure to successfully develop new and/ or improved products (including new versions of existing products) on a timely basis could have a material adverse effect on our results of operations and business. sample
Paragraph 368 · 42% changed Every version of it
We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with applicable rules and regulations of the CMS, the FDA, and other comparable foreign regulatory authorities; provide true, complete and accurate information to such regulatory authorities; comply with manufacturing and clinical laboratory standards; comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; follow our processes and procedures resulting in implementation gaps, poor organization structure or culture, lack of appropriate internal reporting and decision making or substantive weaknesses, for example, in building and maintaining cybersecurity defenses; or report financial information or data accurately or to disclose unauthorized activities to us. For example, in June 2023, our third- party telemedicine provider experienced a software issue that resulted in erroneous test reports being delivered to patients. Since we began commercializing Galleri in the United States, our potential exposure under such laws has increased significantly, and our costs associated with compliance with such laws have, and will likely continue to, increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices, as well as off-label product promotion. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of participant recruitment for clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Even if it is later determined after an action is instituted against us that we were not in violation of these laws, we may be faced with negative publicity, incur significant expenses defending our actions, and have to divert significant management resources from other matters. We expect our exposure to and costs associated with compliance with healthcare fraud and abuse laws to increase significantly if we commercialize additional products in the future.

MD&A

130 paragraphs · 27 new · 75 reworded · 27 gone · 10-K Mar 12, 2026 against Mar 5, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 122 · 50% changed
Generally, we measure We are required to use judgment when applying the goodwill and indefinite-lived intangible assets impairment test. Changes in these estimates could materially affect our assessment of the fair value of the reporting unit based on a present value of future discounted cash flows. The discounted cash flow models indicate the fair value of the reporting units based on the present value of the cash flows that the reporting units are expected to generate in the future. and goodwill and indefinite-lived intangible assets impairment. Significant estimates used in our impairment test include the discounted cash flow models include determination of the weighted average cost of capital, revenue growth rates, long-term rate of growth, growth rates, and forecasted profitability of our business.
Paragraph 107 · 49% changed
During fiscal year 2024, The decrease in net cash used by investing activities was primarily consisted related to proceeds from maturities of marketable securities, net of purchases of marketable securities of $545.8 million and $5.2 million for capital expenditures primarily related to purchases of machinery and equipment for use in our laboratories. securities.
Paragraph 123 · 49% changed
Discount rates were determined using a weighted average cost of capital for risk factors specific to us and other market and industry data. In the most recent analysis, a discount rate of 51.5% was used for the goodwill assessment and 46.5% and 20% was used for the intangible assets assessments. The estimates and assumptions used in our assessment of indefinite-lived intangible assets represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Specifically for the recent goodwill impairment analysis, valuation estimates from financial advisors derived from revenue multiples from peer public companies was used. For the recent indefinite-lived intangible assets impairment analysis, discount rate estimates derived from the American Institute of Certified Public Accountants (“AICPA”) Accounting and Valuation Guide were used. The assumptions used are inherently subject to uncertainty and we note that small changes in these assumptions could have a significant impact on the concluded value.
Paragraph 65 · 47% changed
The increase in cost of screening revenue (exclusive of amortization of intangible assets) of $15.3 million was primarily driven by an increase in test volume. Cost of screening revenue (exclusive of amortization of intangible assets) as a percent of revenue decreased in 2024 primarily 2025 mainly due to improved efficiency the reduction in variable costs of Galleri testing related to scalability with increased Galleri sales volume. performed on our automated platform, partially offset by a 6% decrease in ASP and higher sample reprocessing costs.
Paragraph 80 · 45% changed
The increase decrease in benefit from income taxes of $93.4 $9.2 million or 7% was primarily driven by due to an increase in pretax effective tax book losses rate for fiscal the year 2024 ended December 31, 2025 when compared to fiscal the effective tax rate for the year 2023, with consideration to the impact of the valuation allowance against pre-tax losses, as well as the impairments of intangible assets that reduced the Company’s net deferred tax liabilities. ended December 31, 2024.
Paragraph 106 · 43% changed
The decrease in net cash used by operating activities was primarily driven by an improvement in the net loss, adjusted for non-cash changes of $241.5 million and positive working capital changes of $36.7 million, primarily due to an increase in revenue collections, a decrease in operating expenses primarily driven by a reduction in workforce related to the Restructuring Plan, a decrease in clinical studies of $10.7 million was primarily due to driven by completion of enrollment in our PATHFINDER 2 study and completion of final study visits in our NHS-Galleri Trial. The increase Trial and a decrease in purchases of laboratory supplies and research collaboration expenses of $1.3 million was primarily driven by the completion of the development and validation of our automated platform. platform at the end of 2024 and lower clinical studies sample processing. In addition, prior to the Spin-Off, our stock based compensation was settled in cash and subsequent to the Spin-Off settled in shares.
Paragraph 42 · 42% changed
•Continued development of of, and competition within, the market for MCED testing. Multi-cancer early detection is a relatively novel technology and the market for MCED tests is evolving. We continue to drive MCED as a solution to one of healthcare’s most important challenges. Our performance depends on the extent to which key stakeholders, including current and potential commercial partners, payors and health systems, regulators, policy makers, academic and community medical centers, and key opinion leaders and advocates, understand and support MCED testing as an effective solution for cancer screening. We make significant efforts to educate these key stakeholders regarding the benefits of MCED and the clinical and economic value of our products, which we believe will continue to drive awareness of MCED and expand the commercial opportunity for our products. Additionally, new MCED products from new market entrants launched commercially in the second half of 2025. We believe that the addition of new market entrants will help develop the market for MCED testing. However, these competitors will also be targeting similar markets as us and may compete with us for customers on characteristics of their tests, such as test performance, ease of use and cost. These companies may also present clinical or other information, such as test performance information, that differs from our own presentation of similar information. Our ability to differentiate Galleri from other MCED products and any such presented data will be a key factor in our success. We believe we are differentiated by our extensive and robust datasets generated from our clinical studies, our rigorous and objective approach to test development and research, our multidisciplinary capabilities leveraging the power of next-generation sequencing and advanced and trained machine learning algorithms and data science, our robust intellectual property portfolio, and our investment in our facilities and operational workflows. However, certain new market entrants may have greater financial resources, quicker reimbursement timelines, larger sales forces, more successful marketing campaigns, more experience in screening or international commercialization, lower prices or other advantages. Our ability to succeed will depend on our market success. See Item 1A. “Risk Factors”.
Paragraph 37 · 41% changed
In addition, we have entered into a supply and commercialization agreement with Illumina. Illumina (the “Illumina Supply Agreement”). Under the terms of the agreement, Illumina Supply Agreement, regardless of whether our products incorporate any Illumina technology, we have agreed will be obligated to pay to Illumina a high single-digit 9% royalty, subject to certain reductions, reductions and floors, in perpetuity on net sales generated by our products or revenues otherwise generated or received by us, subject to certain exceptions, in the field of oncology. Per The royalty is subject to anti-stacking provisions that allow royalty payments we make to other third parties to be deducted from the terms 9% royalty rate, to a floor of 7%. We expect that the Separation and Distribution Agreement with Illumina, third party royalty payments we will make in the foreseeable future will result in a 7% royalty rate. After we have cumulatively paid Illumina royalties totaling $1 billion, the royalty arrangement rate will be reduced to 5%, without further adjustment. Pursuant to the fourth amendment to the Illumina Supply Agreement, the perpetual royalty payment obligation to Illumina is suspended until the earlier of December 24, 2026 or any earlier GRAIL Change change of Control (as defined in that agreement), control of GRAIL, at which time royalty payments to Illumina will resume, without retroactive effect. Any royalty payments that we would have made under the high-single digit Illumina Supply Agreement during the suspension period are deemed to have been paid for purposes of the cumulative $1 billion in royalty will become payable. payments required to reduce the royalty rate to 5%.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors425 words changed in this paragraph; it is 37% similar to last year's version.
As a result of the Spin-Off, we are subject to a number of limitations and risks that may impact our ability to obtain additional financing. For example, certain restrictions under the Tax Matters Agreement limit our ability to obtain additional financing, including offerings of common stock, or otherwise require that we undertake certain procedures with Illumina. In addition, certain terms of the Spin-Off may impact our ability to successfully obtain financing on favorable terms or at all. For example, in connection with the Spin-Off, Illumina provided us with disposal funding in the amount of $932.3 million in accordance of the Separation and Distribution Agreement, subject to a clawback feature in the event that the Company (i) consummates a GRAIL Change of Control, or (ii) (1) pays any dividend on, or makes any other distribution in respect of, any shares of its capital stock or other equity or voting interests (other than a stock dividend or a stock split), or otherwise consummates a return of capital from GRAIL to any of its equity holders or (2) redeems, purchases or otherwise acquires any of its outstanding shares of capital stock or other equity or voting interests, in each case prior to the 15-month anniversary of the Distribution Date. If the Company consummates a transaction described in the foregoing clause (i) prior to the 15-month anniversary of the Distribution Date, the Company must return to Illumina a cash amount calculated by reference to the number of months which have elapsed since June 24, 2024 at the time of the public announcement of the event giving rise to such transaction. If the Company consummates a transaction described in the foregoing clause (ii) prior to the 15-month anniversary of the Distribution Date, the Company must return to Illumina a cash amount equal to the payments made by the Company in connection with such transaction up to an aggregate maximum amount equal to the amount of the initial disposal funding subject to a clawback feature in the event of a change in control, or the Company (1) pays any dividend on, or makes any other distribution in respect of, any shares of its capital stock or other equity or voting interests (other than a stock dividend or a stock split), or otherwise consummates a return of capital from GRAIL to any of its equity holders or (2) redeems, purchases or otherwise acquires any of its outstanding shares of capital stock or other equity or voting interests, prior to September 24, 2025. If these clawback features are triggered, we must return to Illumina the aggregate amount of payments to equity holders as a result of or in connection with such a transaction. Additionally, in connection with certain change of control transactions prior to September 24, 2025, we must return to Illumina a cash amount decreasing over time calculated by reference to the number of months which have elapsed since June 24, 2024 at the time of the public announcement of the event giving rise to the change of control. These restrictions under these agreements may impact our ability to obtain additional financing when needed, if at all, and, if we are required to repay any disposal funds to Illumina under the clawback provision, our cash balance will be reduced and we may have greater need for additional financing.

Source: Item 1A, 10-K 0001628280-26-017319 vs Item 1A, 10-K 0001699031-25-000041

MD&A421 words changed in this paragraph; it is 61% similar to last year's version.
•FDA and other regulatory approval and reimbursement. Our performance will be impacted by the extent to which we can secure reimbursement and coverage for Galleri. Prior to broader coverage and reimbursement in the United States, we will continue our work with clinics and health systems to accelerate utilization, and with self-insured employers and health insurers to offer and cover Galleri. Galleri is currently available as a laboratory developed test (“LDT”) in the United States and we have established private coverage and reimbursement from a number of self-insured employers and health plans, including coverage from TRICARE, but we do not currently have broader coverage and reimbursement by government healthcare programs, such as Medicare. Medicare or large commercial insurers. While Galleri has not been approved or cleared by the FDA, FDA approval is currently not required to market our test in the United States. We plan to pursue are pursuing FDA approval to help support broad access for Galleri in the United States. We plan to complete States and we submitted a PMA submission with for Galleri to the FDA in the first half of January 2026. The timing of this submission is subject to various risks and other factors, including the completion of clinical studies and our ongoing discussions with the FDA. Obtaining PMA approval can take several months or years from the time an application is submitted, if at all. Moreover, the FDA regulatory requirements that will govern MCED tests, as well as surrounding the breadth pathway to PMA for laboratory tests has in the recent past, and nature of data we must provide may in the FDA to support the proposed intended use, may future, be subject to change, and as such it is difficult to predict what information we will need to submit to obtain approval of a PMA from the FDA for a proposed intended use. We continue to interact with the FDA regarding the data we must provide the FDA to support our PMA submission for the proposed intended use. change. We believe that FDA approval, if obtained, could unlock coverage from large commercial payors in the United States and we are supporting proposed legislation in the United States States. In February 2026, a new law created a coverage benefit category to enable coverage of FDA-approved MCED tests by Medicare. Medicare, with authority for CMS to initiate coverage as early as January 1, 2029 for the aged 50-65 Medicare population and expanding one age-year at a time annually. If we obtain FDA approval, we expect to pursue coverage through this new law and, subsequently, inclusion of Galleri in the USPSTF’s guideline recommendation, although such inclusion may take years and is not certain even with FDA approval. Should USPSTF recommend Galleri with an A or B recommendation, CMS would then have the authority to expand coverage beyond what is covered under the MCED benefit category. We believe such FDA approval and, to a greater extent, inclusion in USPSTF guideline recommendations would further increase adoption and market acceptance of our tests. Over time, we have and may continue to the extent Galleri becomes more accessible in the United States, we may opt to provide rebates or discounts to certain customers, or reduce pricing in order to access a broader population base and accelerate adoption. In the United Kingdom, we are working with NHS England to complete our NHS-Galleri Trial. The NHS (which is being merged with the Department of Health and Social Care) (the “NHS”) will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, Trial before determining whether to implement the Galleri test in the NHS. Under our agreement with the NHS, these results have met certain success criteria and missed others. As a result, we and NHS England will convene meetings of our joint steering committee to discuss how best to proceed with deployment to the UK population, if at all, considering deployment approaches and which population groups would most benefit. We believe the decision will include considerations such as NHS budget, political priorities, cost-effectiveness and implementation constraints in addition to an evaluation of the final results. We also believe our work with the NHS and the data generated from our NHS-Galleri Trial, if favorable, Trial could help facilitate adoption in other single-payor systems around the world and support evidence of clinical utility worldwide. Although the primary endpoint of statistically significant combined stage 3 and 4 reduction was not observed in the NHS-Galleri Trial, we believe other results from the trial could be compelling to these systems.

Source: Item 7, 10-K 0001628280-26-017319 vs Item 7, 10-K 0001699031-25-000041

Legal Proceedings232 words changed in this paragraph; it is 62% similar to last year's version.
On November 11, 2023, the first of three securities class action complaints was filed against Illumina and certain of its current and former executive officers in the United States District Court for the Southern District of California. The first-filed case is captioned Kangas v. Illumina, Inc. et al., the second-filed case is captioned Roy v. Illumina, Inc. et al., and the third-filed case is captioned Louisiana Sheriffs’ Pension & Relief Fund v. Illumina, Inc. et al. (collectively, the “Actions”). The complaints generally allege, among other things, that defendants made materially false and misleading statements and omitted material facts relating to Illumina’s acquisition of Grail. The complaints seek unspecified damages, interest, fees, and costs. On January 9, 2024, four movants filed motions to consolidate the Actions and to appoint a lead plaintiff (“Lead Plaintiff Motions”). On April 11, 2024, the Court issued an order consolidating the Actions into a single action (captioned in re Illumina, Inc. Securities Litigation No. 23-cv-2082-LL-MMP), and appointed Universal-Investment-Gesellschaft mbH, UI BVK Kapitalverwaltungsgesellschaft mbH, and ACATIS Investment Kapitalverwaltungsgesellschaft mbH as lead plaintiffs. (the “Lead Plaintiffs”). On June 21, 2024, the Lead Plaintiffs filed a consolidated amended complaint. The amended complaint alleges that GRAIL, in addition to Illumina, and certain of their respective current and former directors and others violated sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b-5 in connection with Illumina's acquisition of GRAIL and disclosures concerning the same. GRAIL has an indemnification obligation for certain current and former directors and officers involved in the matter pursuant to indemnification agreements entered into by these individuals and GRAIL. On September 13, 2024 the plaintiffs further amended the complaint. On November 12, 2024, the Company moved to dismiss Lead Plaintiffs’ second amended complaint for failure to state a claim under Sections 10(b) and 20(a) of the Exchange Act. Lead Plaintiffs filed their opposition to the motion to dismiss on December 20, 2024, and the Company filed its reply in support of its motion to dismiss on February 3, 2025. On September 26, 2025, the court granted the motion to dismiss for failure to state a claim with leave to amend, and ordered the plaintiffs to file an amended complaint, if any, by October 27, 2025. On October 27, 2025, the Lead Plaintiffs filed their third amended complaint. On December 12, 2025, the Company filed a motion to dismiss Lead Plaintiffs’ third amended complaint. In light of the fact that the lawsuits are in an early stage, the Company cannot predict the ultimate outcome of the suits.

Source: Item 3, via Note 11 – LEGAL AND REGULATORY PROCEEDINGS, 10-K 0001628280-26-017319 vs Item 3, via Note 10 – LEGAL AND REGULATORY PROCEEDINGS, 10-K 0001699031-25-000041

Accounting Policies129 words changed in this paragraph; it is 41% similar to last year's version.
In December 2023, May 2025, the FASB issued No. ASU No. 2023-09, Income Taxes 2025-04, Compensation-Stock Compensation (Topic 740): Improvement to Income Tax Disclosures. 718) and Revenue from Contracts with Customers (Topic 606). This update address diversity in practice and improves income tax disclosure requirements, primarily through enhanced transparency the operability of accounting for share-based consideration granted to customers. The amendments clarify how to distinguish between service and decision usefulness of disclosures. performance conditions for vesting, require entities to estimate forfeitures for all share-based consideration payable to customers, and specifies that variable consideration guidance in ASC 606 does not apply when measuring such awards. This guidance will be is effective for fiscal years beginning after December 15, 2026, and interim reporting periods within those annual reporting periods beginning the year ended December 31, 2025, periods, with early adoption permitted and can permitted. The transition method may be applied modified retrospective or on either a prospective or retroactive retrospective basis. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements and related disclosures.

Source: Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001628280-26-017319 vs Item 8, Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, 10-K 0001699031-25-000041

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of GRAL's Risk Factors and MD&A, 10-K Mar 12, 2026 against 10-K Mar 5, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Our NHS-Galleri Trial did not meet its stated primary endpoint, which may adversely affect our business, stock price, and ability to obtain regulatory approvals, coverage and reimbursement, or achieve commercial adoption.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
In February 2026, we announced topline results from our NHS-Galleri Trial, which enrolled approximately 140,000 participants in England between 2021 and 2024, and which did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction. Not meeting the stated primary endpoint may negatively impact perceptions of the clinical utility of the Galleri test among healthcare providers, payors, regulators, potential commercial partners, and the investment community. This could adversely affect our ability to obtain coverage and reimbursement from Medicare, Medicaid, and commercial third-party payors, secure implementation of Galleri screening in the NHS in England or other international single-payor healthcare systems, achieve broad commercial adoption of Galleri among healthcare providers and patients in the United States, or enter into partnerships or collaborations on favorable terms. Additionally, although the submission package submitted for our PMA includes only the NHS-Galleri Prevalent Round Results, data from the PATHFINDER 2 Initial Results and the Bridging Analysis, nevertheless it is possible that not meeting the stated primary endpoint in the NHS-Galleri Trial could impact our ability to achieve FDA approval of our pending PMA application, or result in approval with more limited indications or labeling than we seek.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
We are undertaking additional analyses and plan to extend the trial's follow-up period by 6-12 months to further understand the data and other endpoints. However, there can be no assurance that such analyses will produce more favorable conclusions or that any additional data will change perceptions of the trial results among the groups identified above. Any adverse impact from the primary endpoint results could materially harm our business, results of operations, financial condition, and stock price.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
For example, in February 2026, we announced topline results from the NHS-Galleri Trial, which did not achieve its primary endpoint of statistically significant combined Stage 3 and 4 cancer reduction. Not meeting the stated primary endpoint may lead healthcare providers, payors, regulators, and the investment community to question the clinical utility of Galleri. Any perception that our products do not perform as expected, even if clinically meaningful benefits were demonstrated, could materially harm our ability to obtain regulatory approvals, secure reimbursement, achieve commercial adoption, and maintain the market price of our common stock.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
Our clinical trials to date have been conducted on an earlier version of Galleri. We have in the past improved, and intend in the future to improve, our products to enhance performance, offerings, scalability, and/or cost of sales, including through the launches of new versions. However, we may not be successful in transitioning our products to a new or enhanced version or iteration. These improvements may be made through evaluation, refinement or enhancement of our laboratory process or our algorithms and other processes. Before implementing a new version, we conduct a non-inferiority or bridging study (for example, using clinical data and/or real-world evidence data obtained through Galleri’s commercial use as an LDT) to establish performance, safety and concordance between the new version and the existing version. Even if determined to be non-inferior or concordant, these refinements and improvements may inadvertently result in unanticipated issues that may reduce our performance characteristics, such as sensitivity or specificity rates, increase our turnaround time or failure rate or otherwise adversely affect the performance of our tests and their results. For example, in late 2024, we began use of an updated commercial version of Galleri in commercial channels. This version incorporates an industrial scale platform with significant automation and is intended to enable us to scale more efficiently with future demand. In connection with implementation of this new version of Galleri, we initially experienced and may continue to experience increased turnaround times, re-processing costs and sample failures. We continually monitor and evaluate laboratory operations and performance in an effort to achieve our intended sample processing metrics and costs; however from time to time, processing issues may arise that could impact our operations.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
If we are unable to adequately prevent these issues from occurring, or to adequately identify and remedy these issues, we may experience reputational harm, lose customers and revenue, need to offer discounts, require additional expenditures, delay or prevent PMA approval, or suffer other negative consequences. Our failure to successfully develop new and/or improved products (including new versions of existing products) on a timely basis could have a material adverse effect on our results of operations and business.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
statistical power for our endpoints, our product development, commercialization activities, and our ability to seek regulatory clearance or approval for our products could be delayed, require modification, or be prevented.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
In February 2026, the Nancy Gardner Sewell Medicare MCED Coverage Act became law and created a Medicare coverage benefit category for multi-cancer early detection tests. The law included certain standards, including that CMS would establish coverage through a national coverage determination (“NCD”) process under “reasonable and necessary” evidentiary requirements. An NCD typically involves a multi-step review that can include evidence assessment by CMS staff, consultation with external technology assessment organizations, a Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting, and opportunities for public comment. CMS may issue an NCD to provide coverage for MCED tests that are cleared under 510(k), classified under 513(f)(2) or approved by the FDA, with authority to initiate coverage as early as January 1, 2029. Coverage eligibility is phased in, with those aged 50-65 eligible under the law in 2029, expanding by one age-year annually. The payment rate for covered MCED tests would be in alignment with methodologies under the Protecting Access to Medicare Act (PAMA), which incorporates private market rates. The NCD process can be lengthy and resource-intensive, and its timing, outcome, and scope are inherently uncertain, which may affect the availability, extent, and conditions of Medicare reimbursement for applicable products or services. Because of the novelty of the statutory authority and of MCED technology, it is uncertain what evidence will be required in order to achieve an NCD, or if the evidence we have collected through our completed, ongoing or planned clinical studies and commercial practice will be sufficient to support such determination.
Read it in 10-K Mar 12, 2026 at sec.gov
Show the other 67
AddedRisk Factors
Medicare population due to the age restriction and annual phase in requirement. Accordingly, we would intend to seek a USPSTF grade for Galleri and, potentially, an NCD as additional preventative services. If we receive an NCD for Galleri or our other products and subsequently receive a USPSTF grade lower than A or B, it is possible that CMS would rescind the NCD.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
In determining whether to provide coverage and reimbursement for Galleri, payors may consider the results of our clinical studies, including the NHS-Galleri Trial. The NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction. Even though the trial demonstrated a substantial reduction in stage 4 cancer diagnoses, increased stage 1 and 2 detection of deadly cancers, and four-fold higher cancer detection rate when compared to recommended screenings alone, payors may view the overall trial outcome unfavorably, which could adversely impact coverage decisions or reimbursement rates for Galleri. Any inability to secure favorable coverage and reimbursement decisions as a result of the NHS-Galleri Trial results, or otherwise, could materially harm our revenue and growth prospects.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
•the perception among healthcare providers, payors, regulators, and the investment community regarding the clinical significance of clinical trial results, including instances where a trial does not meet its primary endpoint, even if clinically meaningful secondary endpoints are achieved, as occurred in our NHS-Galleri Trial; and
Read it in 10-K Mar 12, 2026 at sec.gov
AddedRisk Factors
•the willingness of healthcare providers and payors to prescribe or cover Galleri in light of the NHS-Galleri Trial not meeting its primary endpoint of statistically significant combined Stage 3 and 4 reduction, notwithstanding favorable secondary endpoint data.
Read it in 10-K Mar 12, 2026 at sec.gov
RemovedRisk Factors
Further, we plan to improve our products to enhance performance, offerings, scalability, and/or cost of goods. However, we may not be successful in transitioning our products to a new or enhanced version or iteration. Product development involves a lengthy and complex process and we may be unable to commercialize, validate, or improve performance of any of our products on a timely basis, or at all. For example, to the extent an enhanced version of an existing product is developed, we may be required to conduct a non-inferiority study involving such enhanced version as compared to the relevant then-current version of the test using data (for example, clinical data and/or real world evidence data obtained through Galleri’s commercial use as an LDT), or could be required to undertake other regulatory requirements if the enhanced version is not considered similar enough to the then-
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
The results of our development efforts and clinical studies of our products conducted to date and ongoing or future studies of our current or future products may not be predictive of the results of later clinical studies, and interim results of a clinical study do not necessarily predict final results. Our interpretation of data and results from our clinical studies do not ensure that we will achieve similar or favorable results in future clinical studies. In addition, clinical data are often susceptible to various interpretations, analyses, and methodological limitations, and many companies that have believed their products performed satisfactorily in earlier clinical studies have nonetheless failed to replicate results in later clinical studies. Products in later future clinical studies may fail to show the desired safety and efficacy despite having success in previous clinical studies.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
For example, our PMA submission for Galleri requires clinical data, including certain data from our ongoing PATHFINDER 2 study, which we are conducting under an FDA-approved Investigational Device Exemption (“IDE”) application and our NHS-Galleri Trial. We may encounter difficulties enrolling or maintaining a sufficient number of participants in our current or future studies. Delays in our studies would cause us to delay completion
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
planned clinical studies used to support our PMA submission, which could lead healthcare providers, payors, and others to lose confidence in the utility or benefit of Galleri and our other products and future products.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
Our success will depend on the market’s confidence that our products, including Galleri and, if successfully developed and launched, further enhanced versions of Galleri, and our precision oncology portfolio can provide reliable, high-quality results. We believe that participants, patients, customers, physicians, and regulators are
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
materially harmed. Although we carry insurance for damage to our properties and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
we have employment agreements with certain key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize highly qualified personnel on acceptable terms in a timely manner, or at all, our business and results of operations may suffer.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
In addition, in recent years, U.S. administrations have publicly supported potential trade proposals that may affect U.S. trade relations with other countries. It is unclear at this point how, if at all, such actions or other potential actions, including under the new U.S. Presidential administration, may impact our business or
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
We, along with companies with whom we engage in data sharing, including our service providers, are from time to time subject to cyberattacks and other cybersecurity incidents. While we do not believe that we have experienced any significant system failure, or cybersecurity incident to date, we may nonetheless be a target of such an attack, and if such an event were to occur and cause interruptions in our operations, or any of our third-party collaborators’ operations, it could result in a material disruption of our development programs, reputation, and business operations whether due to a loss, corruption, or unauthorized disclosure of our trade secrets, personal information, financial information, health information, or other proprietary or sensitive information, or other similar disruptions. For example, the loss of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory clearance, approval, or certification efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize our products. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer a cybersecurity incident or attack, for example, that resulted in the unauthorized access to or use or disclosure of personal or health
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedRisk Factors
Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. In particular, developments in artificial intelligence tools and computing power, are likely to increase the frequency and effectiveness of attacks. We may also experience cybersecurity incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate cybersecurity incidents due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.
Read it in 10-K Mar 5, 2025 at sec.gov
RewordedRisk Factors
It Further, it is possible that the early preliminary, interim or final data may not be as we expect, may be inconsistent with prior NHS-Galleri Trial data, or with other studies we have conducted, or may be unsuitable to the NHS, any of which could have a significant adverse impact on NHS or the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our ability to achieve CMS or private payor reimbursement or coverage, our brand and reputation, our business, and our growth prospects. FDA.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
For example, Washington State has enacted a broadly applicable law to protect the privacy of personal health information known as the “My Health My Data Act,” which generally requires affirmative consent for the collection, use, or sharing of any broadly defines “consumer health data. data”, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants consumers certain rights with respect to their health data, including to request deletion of their information.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
The To this end, on May 6, 2024, the FDA proposed issued a final rule in an amendment to its regulations in October 2023 effort to clarify the FDA’s historical view that LDTs are medical devices subject to the requirements applicable to other IVDs, IVDs (the “LDT Final Rule”), and to phase out its enforcement discretion policy over a period of four years from issuance of the final rule, which would involve a phase-in of medical device requirements to these products over this time period. LDT Final Rule.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Our PMA submission and a potential subsequent Potential rejection or material delay, delay of our PMA submission, including a requirement by the FDA to conduct additional studies or expand the enrollment of completed or ongoing studies, may reflect negatively on Galleri and the ongoing clinical studies used to support our PMA submission, which could lead healthcare providers, payors, and others to lose confidence in the utility or benefit of Galleri and our other products and future products.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Our products or future products may not perform as expected, and the results of our clinical studies may not support the launch or use of our products or future products and may not comply with the requirements, or be replicated in later studies or in the post-market or real-world setting, required to support a commercial opportunity or for any necessary or desirable regulatory clearances, approvals, or certifications, or reimbursement or coverage. setting.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
For example, as As a part of our overall public company preparedness efforts in connection with the Spin-Off in 2024, cybersecurity program, we underwent conduct a number of internal evaluations and independent, external third-party reviews of our cybersecurity program against audits and reviews, including under the NIST CSF 2.0 and NIST Privacy Framework, Frameworks, along with our ordinary course annual reviews under ISO 27001, SOC2 Type 2, PCI DSS, HIPAA, and other standards, in order to identify capabilities, gaps, and recommendations for improvement, and to compare our cybersecurity program to applicable requirements.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Our short operating history as a company, evolving business strategies, rapid growth and significant events such as our separation from Illumina and the Restructuring Plan restructuring plan (“Restructuring Plan”) approved by our Board of Directors (the “Board”) designed to reprioritize our resources to focus on our core MCED business and reduce overall spend as we pursue a PMA approval from the FDA for Galleri and broad reimbursement, may make it difficult to evaluate our current business or our future success and the risks and challenges we may encounter, and may increase the risk that we will not continue to grow at or near historical rates.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
It is possible that the early preliminary, interim Any unexpected, unsuitable, or final data may not be as we expect, may be inconsistent with prior NHS-Galleri data, or with other studies we have conducted, or may be unsuitable to the NHS, any of which results could have a significant adverse impact on the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our ability to achieve CMS or private payor reimbursement or coverage, our brand and reputation, our business, and our growth prospects.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
For example, the potential commercialization of Galleri with the NHS, subject to the full results of the NHS-Galleri Trial, Trial which we expect to report in mid-2026, will be considered by the government of the United Kingdom and may be delayed or otherwise impacted if there is a change in depending on the circumstances and the composition of the government in at the United Kingdom. time of consideration.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Noncompliance In addition to potential fines, noncompliance with applicable foreign privacy laws, such as the GDPR, would also adversely affect may result in regulatory investigations, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit), civil claims (including class actions) and/or damage to the public perception of GRAIL’s data stewardship practices and policies, which could impair our business and prospects with other foreign health systems and governments.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Specifically, this final rule, The QMSR, which replaced the FDA expects to go into effect on February 2, 2026, replaces the QSR with the FDA’s former Quality Management System Regulation (“QMSR”), (“QSR”), sets forth the FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedRisk Factors
Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, Accordingly, it is remains unclear the extent to which this final rule, once effective, could the QMSR may impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise create market pressure that may negatively affect our business.
Read it in 10-K Mar 12, 2026 at sec.gov
Quiet changesRisk Factors
As a result, any disruption at our North Carolina facility could materially adversely affect our ability to process tests and return results to patients, and our revenue, operations, business and prospects could be materially harmed.
Read it in 10-K Mar 12, 2026 at sec.gov
Quiet changesRisk Factors
To achieve compliance with SOX Section 404 within the prescribed period, we will be are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
across this clinical program and from our commercial experience, including through partnerships with leading healthcare systems, employers, digital health platforms, payors, and life insurance providers.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
Recently we announced results from two of our large clinical trials, PATHFINDER 2 and NHS-Galleri Trial, and included certain results from those studies in our pre-market approval application (“PMA”) to the Food and Drug Administration (“FDA”), the last module of which we submitted in January 2026. Performance and safety data focused on the first approximately 25,000 participants of our approximately 35,000 participant PATHFINDER 2 study were presented at the European Society for Medical Oncology (“ESMO”) in October 2025 (the “PATHFINDER 2 Initial Results”) and demonstrated that adding Galleri to recommended (breast, cervical, colorectal and lung) screenings led to a cancer detection rate more than seven-fold increase in the number of cancers found within a year, and an approximately three-fold increase when prostate screening was included. Results from the full approximately 35,000 participants in the PATHFINDER 2 study were generally consistent with the results presented at ESMO. We also announced topline results from our three year, randomized control NHS-Galleri Trial which demonstrated a substantial reduction in stage 4 cancer diagnoses, increased stage 1 and 2 detection of deadly cancers, and four-fold higher cancer detection rate when compared to recommended screenings alone, although the primary endpoint of statistically significant combined stage 3 and 4 reduction was not observed. However, there was a favorable trend toward fewer combined stage 3 and 4 cancers in a pre-specified group of 12 deadly cancers in the intervention arm after the prevalent screening round. The PATHFINDER 2 Initial Results and the performance and safety metrics from the first year (prevalent screening round) of our NHS-Galleri Trial (“NHS-Galleri Prevalent Screening Round Results”) were included in our PMA submission, along with results of a bridging study.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
We designed Galleri to detect cancer early, when it is more amenable to curative treatment, and we launched Galleri in the United States in mid-2021. Galleri works by detecting DNA fragments shed into the bloodstream by tumor cells and analyzing specific methylation patterns that can be used to both identify a general cancer signal and localize that signal to a specific organ or tissue type. We have sold approximately 475,000 commercial Galleri tests through December 31, 2025, including more than 185,000 in 2025, which have detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
As an early pioneer of MCED testing, we have established strong relationships within the cancer and primary care community, including through partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. We have shared evidence supporting our MCED testing at renowned medical conferences, such as the American Association of Cancer Research (“AACR”), American Society of Clinical Oncology (“ASCO”), ESMO, and American Academy of Family Physicians (“AAFP”). We have also published results from our studies in leading scientific and medical journals, including The Lancet, Nature, Nature Medicine, Cancer Cell, and The Lancet Oncology.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
On October 18, 2025, we entered into a securities purchase agreement (the "Purchase Agreement") with certain investors for the private placement of (i) 2,640,970 shares of GRAIL's common stock at a price of $70.05 per share and (ii) pre-funded warrants to purchase an aggregate of 1,998,573 shares of GRAIL’s common stock (the "Pre-Funded Warrants") at a purchase price of $70.049 per Pre-Funded Warrant, which represents the per share price for the common stock less the $0.001 exercise price. The PIPE closed on October 21, 2025, at which time we received aggregate net proceeds of $311.3 million, after deducting issuance costs of $13.7 million.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
In addition, in connection with the Purchase Agreement, we entered into a Registration Rights Agreement with all of the investors (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, we filed a registration statement on Form S-3 with the SEC on November 13, 2025 for purposes of registering the resale of the shares and the shares of common stock issuable upon exercise of the Pre-Funded Warrants purchased in the private placement.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
On November 14, 2025, we entered into an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents, establishing an At the Market Equity Distribution Program, under which we may offer and sell shares of our common stock, having an aggregate offering price of $300.0 million or up to 6,900,000 of common stock shares (the “ATM Program”).
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
During the year ended December 31, 2025, we issued 1,169,218 shares of our common stock pursuant to the ATM Program and we received aggregate net proceeds of $107.5 million, after deducting issuance costs of $3.2 million. As of December 31, 2025, $189.3 million worth of shares of common stock remained available for sale pursuant to the ATM Program.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
In October 2025, we announced a strategic collaboration with Samsung C&T Corporation (“Samsung C&T”), Samsung Electronics Singapore Pte. Ltd. (together with Samsung C&T, the “Samsung Investors”) and Samsung Electronics Co., Ltd. (“Samsung Electronics”). As part of this strategic collaboration, we and Samsung C&T intend to work as exclusive partners to commercialize Galleri in Korea and, potentially, other key Asian markets, including Japan and Singapore. In addition, we and Samsung Electronics intend to explore potential additional strategic and operational collaborations, such as supporting longitudinal genomic-lifestyle clinical research and the integration of Samsung Electronics’ health data platform with our technologies and data.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
In connection with this strategic collaboration, we entered into a stock purchase agreement (the “Samsung Stock Purchase Agreement”), with the Samsung Investors and Samsung Electronics, providing for the issuance and sale by us to the Samsung Investors in a private placement of 1,570,308 shares of our common stock, at a purchase price of $70.05 per share, upon the terms and conditions set forth in the Samsung Stock Purchase Agreement, for aggregate gross proceeds of approximately $110.0 million (the “Samsung Investment”). The Samsung Investment is subject to the satisfaction of certain closing conditions set forth in the Samsung Stock Purchase Agreement, including, but not limited to the satisfaction of certain regulatory approvals or clearances, including with respect to the Committee on Foreign Investment in the United States.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
We intend to use the net proceeds from all our equity offerings to fund our commercial activities and reimbursement efforts, as well as for working capital and other general corporate purposes.
Read it in 10-K Mar 12, 2026 at sec.gov
AddedMD&A
We entered into or adopted agreements that provide a framework for the relationship between us and Illumina in connection with the Spin-Off. Refer to Note 1 — Organization And Description Of Business in Item 8 in this Annual Report on Form 10K.
Read it in 10-K Mar 12, 2026 at sec.gov
RemovedMD&A
A detailed discussion comparing our results of operations for the years ended December 31, 2023 and January 2, 2022 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our final Information Statement filed with our Registration Statement on Form 10, as amended, as filed with the SEC.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
On June 24, 2024, Illumina completed the Spin-Off, as described above. See Note 1 — Organization And Description Of Business for details. In connection with the Spin-Off, certain equity and liability classified awards were converted in accordance with the employee matters agreement, as further described in Note 7 — Stock-Based Compensation. As a result of the separation, our member’s equity balance was reclassified to additional paid-in capital.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
While GRAIL was a subsidiary of Illumina, GRAIL’s fiscal year was the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to “fiscal year 2023” refer to the period from January 2, 2023 to December 31, 2023, and “fiscal year 2024” refer to the period from January 1, 2024 to December 31, 2024. Upon the closing of the Spin-Off, GRAIL adopted a fiscal year end of December 31.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
opportunities and we have begun expansion in select additional geographies through distributors. We expect to continue selectively engaging with international opportunities over time.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
•Leverage our operational infrastructure. We have made significant investments to build a scalable infrastructure capable of meeting significant demand while satisfying applicable certification requirements. Our Durham, North Carolina facility is able to process a substantial number of tests
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
On July 13, 2022, the European General Court ruled that the European Commission had jurisdiction under the European Union Merger Regulation to review the Acquisition. Additionally, on September 6, 2022, the European Commission issued a decision prohibiting the Acquisition. These decisions constituted substantive changes in circumstances that would more likely than not reduce the fair value of goodwill. We recognized a goodwill impairment for $4.7 billion in 2022. In the third quarter of 2023, we concluded the sustained decrease in Illumina’s stock price and overall market capitalization during the quarter was a triggering event indicating the fair value of GRAIL might be less than its carrying amount that led us to test goodwill for impairment. We recognized an additional goodwill impairment of $608.5 million in 2023 primarily due to changes to expected timing of revenue and a higher discount rate. In the second quarter of 2024, prior to the Spin-Off, the approval of the Spin-Off by Illumina’s board of directors represented a potential indicator of impairment which also aligned with the timing of Illumina’s annual goodwill impairment test date for 2024. We recognized a goodwill impairment of $888.9 million as a result of the impairment assessment, primarily due to changes to the forecast of GRAIL’s value and the method for valuing GRAIL.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
In conjunction with the third quarter of 2023 goodwill impairment assessment described above, the Company also evaluated the IPR&D intangible asset for potential impairment. Based on the impairment test performed, the Company recognized an impairment of $110.0 million, primarily due to a decrease in projected cash flows and a higher discount rate selected for the fair value calculation. In conjunction with Illumina’s second quarter of 2024 goodwill impairment assessment, the IPR&D intangible asset of the GRAIL reporting unit was evaluated for potential impairment by Illumina prior to the Spin-Off. Based on the impairment test performed, the Company recognized an impairment of $420.0 million primarily due to changes to revenue projections and the discount rate utilized. Subsequent to the Spin-Off, the Company performed a portfolio review and determined to decrease investment in the development of the IPR&D asset, which impacted the amount and timing of expected future cash flows attributable to IPR&D which represented a potential impairment indicator. Based on the impairment test performed, the Company recognized an additional impairment of $112.0 million, primarily due to a decrease in projected cash flows.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
Upon closing of the Acquisition, as a wholly owned subsidiary of Illumina, we were no longer subject to U.S. income tax on a standalone basis and U.S. income tax was combined into Illumina’s consolidated income tax return as a subsidiary of Illumina. However, for financial statement purposes, we have elected to compute our income tax provision, including current and deferred taxes, as if we filed a separate income tax return and were not included in Illumina’s consolidated return for the period GRAIL was owned by Illumina. Including the provision for income taxes in our standalone financials is more representative of our financial position as a standalone company. As such, the income tax provisions and related deferred tax assets and liabilities reflected in our financial statements for the periods ending December 31, 2023 and January 1, 2023 have been estimated as if we were a separate taxpayer.
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
Under this method, various tax attributes, such as net operating losses and tax credits, are also presented on a separate return basis. For income tax purposes, since we were not a separate taxpayer and merely a subsidiary of Illumina, these tax attributes, including net operating losses and tax credits, are the property of
Read it in 10-K Mar 5, 2025 at sec.gov
RemovedMD&A
Illumina and have either already been utilized by Illumina in its consolidated or combined income tax returns or will be utilized by Illumina in its returns in the future. Accordingly, such tax attributes will not be available to us as a standalone entity on our income tax returns in the future; therefore, in connection with the Spin-off, we recorded an entry to additional paid in capital in order to remove the tax-effected deferred tax assets, net of any valuation allowance, for the tax attributes that remained the property of Illumina. Following the Spin-off, as a standalone entity, GRAIL files tax returns on its own behalf and its deferred taxes and actual income tax rate may differ from those in historical periods.
Read it in 10-K Mar 5, 2025 at sec.gov
RewordedMD&A
The decrease in sales and marketing expenses of $8.3 $37.3 million or 24% was primarily attributable to a decrease of $2.5 million in compensation expenses of $26.1 million, primarily related due to a $17.4 million decrease in salaries and wages of $4.9 million, wages, a $4.8 million decrease in severance and benefits, and a $4.4 million decrease in stock-based compensation of $2.2 million, and a decrease of $0.3 million in variable compensation expense expense, primarily due to the reduction in workforce reductions related to the Restructuring Plan, partially offset by a $4.9 million increase Plan implemented in severance and benefits related to the Restructuring Plan. 2024.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
We calculate Adjusted EBITDA as net income (loss) loss adjusted to exclude interest (income) expense, income tax expense (benefit), depreciation, impairment of goodwill and intangible assets, and amortization of intangible assets, which represent stock-based compensation, depreciation, goodwill and intangible assets resulting impairment, restructuring, interest income, benefit from pushdown accounting, income tax expense, and legal and professional services fees costs related to the Acquisition and corresponding antitrust litigation, including compliance with the hold separate arrangements imposed by the European Commission Commission, and our divestment from Illumina, restructuring charges, and stock-based compensation. Illumina.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
In these studies, Galleri demonstrated an ability to detect a shared cancer signal across more than 50 Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predict predicting the specific organ or tissue type where the cancer signal originated, and yield originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
We expect our sales and marketing expenses to decrease increase following the release of positive study results as we invest in the near term following implementation initiatives to drive awareness and demand generation of the Restructuring Plan in the third Galleri and fourth quarter 2024, and then to remain flat-to-increasing and continue to decrease as a percentage of revenue over the next three years and long term.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
The A decrease in clinical studies laboratory supplies and research collaborations of $10.7 $28.5 million was primarily due to driven by the substantial completion of the development and validation of our automated platform, the completion of enrollment in our the PATHFINDER 2 study and the completion of final study visits in our the NHS-Galleri Trial. Trial in 2024.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
Cost of screening revenue (exclusive of amortization of intangible assets) as a percent of revenue decreased in 2024 primarily 2025 mainly due to improved efficiency the reduction in variable costs of Galleri testing related to scalability with increased Galleri sales volume. performed on our automated platform, partially offset by a 6% decrease in ASP and higher sample reprocessing costs.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
We expect our G&A expenses to decrease increase as we continue to invest in corporate infrastructure to support public company operations and the near term following implementation commercialization of the Restructuring Plan in the third Galleri and fourth quarter 2024, and then remain flat-to-increasing and to continue to decrease as a percentage of revenue over the next three years and long term.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
The In the United Kingdom, NHS England (which is being merged with the Department of Health and Social Care) (the “NHS”) will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, Trial before determining whether to implement the Galleri test in the NHS.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
The increase decrease in general and administrative expenses of $13.6 $54.8 million or 26% was primarily attributable to an increase of $12.3 million decreases in legal and professional services expenses primarily associated with divestiture and compensation related advisory costs related to our Spin-Off completed on June 24, 2024. expenses.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
On June 24, 2024, Illumina The Spin-Off was completed the previously announced spin-off of GRAIL (the “Spin-Off”) through a distribution of approximately 85.5% of our outstanding common stock to the holders of record of Illumina’s common stock as of the close of business on June 13, 2024 (the “Distribution”). “Distribution”), which resulted in the issuance of 31,049,148 shares of common stock.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
The increase of $3.0 million A decrease in allocated expenses was of $11.2 million primarily attributable related to higher ongoing cost reduction efforts, which resulted in lower software, IT, and facilities expenses being allocated to the research and development function. function, as well as reduced headcount.
Read it in 10-K Mar 12, 2026 at sec.gov
RewordedMD&A
The increase in cost of screening revenue (exclusive of amortization of intangible assets) of $15.3 $10.0 million or 16% was primarily driven by an a 36% increase in test volume. Galleri sales volume, partially offset by a reduction in variable costs of Galleri testing performed on our automated platform.
Read it in 10-K Mar 12, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.